INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28601, 28069, 'Tolterodine', 'Kidney Diseases', 'The renal elimination of tolterodine and active metabolite is limited and a prolonged half-life is not anticipated in patients with renal impairment.  However, the pharmacokinetic disposition of tolterodine has not been evaluated in patients with renal impairment and it is recommended that tolterodine be administered cautiously in patients with compromised renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28602, 28257, 'Tolterodine', 'Kidney Diseases', 'The renal elimination of tolterodine and active metabolite is limited and a prolonged half-life is not anticipated in patients with renal impairment.  However, the pharmacokinetic disposition of tolterodine has not been evaluated in patients with renal impairment and it is recommended that tolterodine be administered cautiously in patients with compromised renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28603, 28262, 'Tolterodine', 'Kidney Diseases', 'The renal elimination of tolterodine and active metabolite is limited and a prolonged half-life is not anticipated in patients with renal impairment.  However, the pharmacokinetic disposition of tolterodine has not been evaluated in patients with renal impairment and it is recommended that tolterodine be administered cautiously in patients with compromised renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28604, 28819, 'Tolterodine', 'Kidney Diseases', 'The renal elimination of tolterodine and active metabolite is limited and a prolonged half-life is not anticipated in patients with renal impairment.  However, the pharmacokinetic disposition of tolterodine has not been evaluated in patients with renal impairment and it is recommended that tolterodine be administered cautiously in patients with compromised renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28605, 28848, 'Tolterodine', 'Kidney Diseases', 'The renal elimination of tolterodine and active metabolite is limited and a prolonged half-life is not anticipated in patients with renal impairment.  However, the pharmacokinetic disposition of tolterodine has not been evaluated in patients with renal impairment and it is recommended that tolterodine be administered cautiously in patients with compromised renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28606, 28849, 'Tolterodine', 'Kidney Diseases', 'The renal elimination of tolterodine and active metabolite is limited and a prolonged half-life is not anticipated in patients with renal impairment.  However, the pharmacokinetic disposition of tolterodine has not been evaluated in patients with renal impairment and it is recommended that tolterodine be administered cautiously in patients with compromised renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28607, 0, 'Tolevamer', 'Hypokalemia', 'The use of sodium polystyrene sulfonate is contraindicated in patients with hypokalemia.  Serious potassium deficiency can occur from therapy with sodium polystyrene sulfonate.  Sodium polystyrene sulfonate exchanges sodium ions for potassium ions in the intestine or colon.  Monitoring serum potassium levels carefully and evaluating the patient''s clinical condition and electrocardiogram may be necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28608, 0, 'Tolevamer', 'Ileus', 'The use of sodium polystyrene sulfonate is contraindicated in patients with obstructive bowel disease.  Cases of intestinal necrosis, which may be fatal, and other serious gastrointestinal adverse events (bleeding, ischemic colitis, perforation) have been reported in association with sodium polystyrene sulfonate use.  Therapy with this agent should be avoided in patients who have not had a bowel movement post-surgery, and patients who are at risk of developing constipation or impaction.  Therapy with sodium polystyrene sulfonate should be discontinued in patients who develop constipation during treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28609, 0, 'Tolevamer', 'Edema', 'The use of sodium polystyrene sulfonate is associated with an elevation in sodium.  Therapy with sodium polystyrene sulfonate should be administered cautiously in patients with conditions that might be exacerbated by additional sodium such as severe congestive heart failure, severe hypertension, or marked edema.  Compensatory restriction of sodium intake from other sources may be indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28610, 23739, 'Tolvaptan', 'Liver Failure', 'Tolvaptan can cause serious and potentially fatal liver injury.  Patients with symptoms that indicate liver injury such as fatigue, anorexia, right upper abdominal pain, dark urine or jaundice should discontinue treatment right away.  Therapy duration should be limited to 30 days.  The use of tolvaptan should be avoided in patients with underlying liver disease, including cirrhosis, because the ability to recover from liver injury may be impaired.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28611, 23739, 'Tolvaptan', 'Kidney Diseases', 'There are no clinical trials of tolvaptan in patients with CrCl < 10 mL/min, and because drug effects on serum sodium levels are likely lost at very low levels of renal function, use in these patients is not recommended.  Additionally, no benefit can be expected in anuric patients, so the use of tolvaptan is contraindicated in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28612, 23739, 'Tolvaptan', 'Liver Diseases', 'Osmotic demyelination syndrome is a risk associated with overly rapid correction of hyponatremia (> 12 mEq/L/24 hours).  This syndrome can result in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizure, coma or death.  Patients with advanced liver disease, alcoholism or severe malnutrition are at increased risk and require slower rates of correction.  Serum sodium concentration and neurological status should be monitored appropriately during treatment administration.  Vasopressin antagonists should be initiated and re- initiated in patients only in hospital settings were sodium levels can be monitored closely.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28613, 3025, 'Topiramate', 'Bone Marrow Failure Disorders', 'The use of carbonic anhydrase inhibitors may rarely cause bone marrow suppression and blood dyscrasias at recommended dosages.  Aplastic anemia, thrombocytopenia or thrombocytopenia purpura, leukopenia, agranulocytosis, and hemolytic anemia have been reported.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered to patients with these preexisting conditions.  A baseline CBC and platelet count is recommended, as well as monitoring at regular intervals during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28614, 3026, 'Topiramate', 'Bone Marrow Failure Disorders', 'The use of carbonic anhydrase inhibitors may rarely cause bone marrow suppression and blood dyscrasias at recommended dosages.  Aplastic anemia, thrombocytopenia or thrombocytopenia purpura, leukopenia, agranulocytosis, and hemolytic anemia have been reported.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered to patients with these preexisting conditions.  A baseline CBC and platelet count is recommended, as well as monitoring at regular intervals during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28615, 8555, 'Topiramate', 'Bone Marrow Failure Disorders', 'The use of carbonic anhydrase inhibitors may rarely cause bone marrow suppression and blood dyscrasias at recommended dosages.  Aplastic anemia, thrombocytopenia or thrombocytopenia purpura, leukopenia, agranulocytosis, and hemolytic anemia have been reported.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered to patients with these preexisting conditions.  A baseline CBC and platelet count is recommended, as well as monitoring at regular intervals during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28616, 11537, 'Topiramate', 'Bone Marrow Failure Disorders', 'The use of carbonic anhydrase inhibitors may rarely cause bone marrow suppression and blood dyscrasias at recommended dosages.  Aplastic anemia, thrombocytopenia or thrombocytopenia purpura, leukopenia, agranulocytosis, and hemolytic anemia have been reported.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered to patients with these preexisting conditions.  A baseline CBC and platelet count is recommended, as well as monitoring at regular intervals during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28617, 16780, 'Topiramate', 'Bone Marrow Failure Disorders', 'The use of carbonic anhydrase inhibitors may rarely cause bone marrow suppression and blood dyscrasias at recommended dosages.  Aplastic anemia, thrombocytopenia or thrombocytopenia purpura, leukopenia, agranulocytosis, and hemolytic anemia have been reported.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered to patients with these preexisting conditions.  A baseline CBC and platelet count is recommended, as well as monitoring at regular intervals during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28618, 17218, 'Topiramate', 'Bone Marrow Failure Disorders', 'The use of carbonic anhydrase inhibitors may rarely cause bone marrow suppression and blood dyscrasias at recommended dosages.  Aplastic anemia, thrombocytopenia or thrombocytopenia purpura, leukopenia, agranulocytosis, and hemolytic anemia have been reported.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered to patients with these preexisting conditions.  A baseline CBC and platelet count is recommended, as well as monitoring at regular intervals during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28619, 18427, 'Topiramate', 'Bone Marrow Failure Disorders', 'The use of carbonic anhydrase inhibitors may rarely cause bone marrow suppression and blood dyscrasias at recommended dosages.  Aplastic anemia, thrombocytopenia or thrombocytopenia purpura, leukopenia, agranulocytosis, and hemolytic anemia have been reported.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered to patients with these preexisting conditions.  A baseline CBC and platelet count is recommended, as well as monitoring at regular intervals during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28620, 18428, 'Topiramate', 'Bone Marrow Failure Disorders', 'The use of carbonic anhydrase inhibitors may rarely cause bone marrow suppression and blood dyscrasias at recommended dosages.  Aplastic anemia, thrombocytopenia or thrombocytopenia purpura, leukopenia, agranulocytosis, and hemolytic anemia have been reported.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered to patients with these preexisting conditions.  A baseline CBC and platelet count is recommended, as well as monitoring at regular intervals during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28621, 18429, 'Topiramate', 'Bone Marrow Failure Disorders', 'The use of carbonic anhydrase inhibitors may rarely cause bone marrow suppression and blood dyscrasias at recommended dosages.  Aplastic anemia, thrombocytopenia or thrombocytopenia purpura, leukopenia, agranulocytosis, and hemolytic anemia have been reported.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered to patients with these preexisting conditions.  A baseline CBC and platelet count is recommended, as well as monitoring at regular intervals during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28622, 27427, 'Topiramate', 'Bone Marrow Failure Disorders', 'The use of carbonic anhydrase inhibitors may rarely cause bone marrow suppression and blood dyscrasias at recommended dosages.  Aplastic anemia, thrombocytopenia or thrombocytopenia purpura, leukopenia, agranulocytosis, and hemolytic anemia have been reported.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered to patients with these preexisting conditions.  A baseline CBC and platelet count is recommended, as well as monitoring at regular intervals during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28623, 27428, 'Topiramate', 'Bone Marrow Failure Disorders', 'The use of carbonic anhydrase inhibitors may rarely cause bone marrow suppression and blood dyscrasias at recommended dosages.  Aplastic anemia, thrombocytopenia or thrombocytopenia purpura, leukopenia, agranulocytosis, and hemolytic anemia have been reported.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered to patients with these preexisting conditions.  A baseline CBC and platelet count is recommended, as well as monitoring at regular intervals during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28624, 27429, 'Topiramate', 'Bone Marrow Failure Disorders', 'The use of carbonic anhydrase inhibitors may rarely cause bone marrow suppression and blood dyscrasias at recommended dosages.  Aplastic anemia, thrombocytopenia or thrombocytopenia purpura, leukopenia, agranulocytosis, and hemolytic anemia have been reported.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered to patients with these preexisting conditions.  A baseline CBC and platelet count is recommended, as well as monitoring at regular intervals during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28625, 28295, 'Topiramate', 'Bone Marrow Failure Disorders', 'The use of carbonic anhydrase inhibitors may rarely cause bone marrow suppression and blood dyscrasias at recommended dosages.  Aplastic anemia, thrombocytopenia or thrombocytopenia purpura, leukopenia, agranulocytosis, and hemolytic anemia have been reported.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered to patients with these preexisting conditions.  A baseline CBC and platelet count is recommended, as well as monitoring at regular intervals during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28626, 28296, 'Topiramate', 'Bone Marrow Failure Disorders', 'The use of carbonic anhydrase inhibitors may rarely cause bone marrow suppression and blood dyscrasias at recommended dosages.  Aplastic anemia, thrombocytopenia or thrombocytopenia purpura, leukopenia, agranulocytosis, and hemolytic anemia have been reported.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered to patients with these preexisting conditions.  A baseline CBC and platelet count is recommended, as well as monitoring at regular intervals during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28627, 28297, 'Topiramate', 'Bone Marrow Failure Disorders', 'The use of carbonic anhydrase inhibitors may rarely cause bone marrow suppression and blood dyscrasias at recommended dosages.  Aplastic anemia, thrombocytopenia or thrombocytopenia purpura, leukopenia, agranulocytosis, and hemolytic anemia have been reported.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered to patients with these preexisting conditions.  A baseline CBC and platelet count is recommended, as well as monitoring at regular intervals during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28628, 28298, 'Topiramate', 'Bone Marrow Failure Disorders', 'The use of carbonic anhydrase inhibitors may rarely cause bone marrow suppression and blood dyscrasias at recommended dosages.  Aplastic anemia, thrombocytopenia or thrombocytopenia purpura, leukopenia, agranulocytosis, and hemolytic anemia have been reported.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered to patients with these preexisting conditions.  A baseline CBC and platelet count is recommended, as well as monitoring at regular intervals during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28629, 28329, 'Topiramate', 'Bone Marrow Failure Disorders', 'The use of carbonic anhydrase inhibitors may rarely cause bone marrow suppression and blood dyscrasias at recommended dosages.  Aplastic anemia, thrombocytopenia or thrombocytopenia purpura, leukopenia, agranulocytosis, and hemolytic anemia have been reported.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered to patients with these preexisting conditions.  A baseline CBC and platelet count is recommended, as well as monitoring at regular intervals during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28630, 28330, 'Topiramate', 'Bone Marrow Failure Disorders', 'The use of carbonic anhydrase inhibitors may rarely cause bone marrow suppression and blood dyscrasias at recommended dosages.  Aplastic anemia, thrombocytopenia or thrombocytopenia purpura, leukopenia, agranulocytosis, and hemolytic anemia have been reported.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered to patients with these preexisting conditions.  A baseline CBC and platelet count is recommended, as well as monitoring at regular intervals during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28631, 28333, 'Topiramate', 'Bone Marrow Failure Disorders', 'The use of carbonic anhydrase inhibitors may rarely cause bone marrow suppression and blood dyscrasias at recommended dosages.  Aplastic anemia, thrombocytopenia or thrombocytopenia purpura, leukopenia, agranulocytosis, and hemolytic anemia have been reported.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered to patients with these preexisting conditions.  A baseline CBC and platelet count is recommended, as well as monitoring at regular intervals during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28632, 28334, 'Topiramate', 'Bone Marrow Failure Disorders', 'The use of carbonic anhydrase inhibitors may rarely cause bone marrow suppression and blood dyscrasias at recommended dosages.  Aplastic anemia, thrombocytopenia or thrombocytopenia purpura, leukopenia, agranulocytosis, and hemolytic anemia have been reported.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered to patients with these preexisting conditions.  A baseline CBC and platelet count is recommended, as well as monitoring at regular intervals during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28633, 28339, 'Topiramate', 'Bone Marrow Failure Disorders', 'The use of carbonic anhydrase inhibitors may rarely cause bone marrow suppression and blood dyscrasias at recommended dosages.  Aplastic anemia, thrombocytopenia or thrombocytopenia purpura, leukopenia, agranulocytosis, and hemolytic anemia have been reported.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered to patients with these preexisting conditions.  A baseline CBC and platelet count is recommended, as well as monitoring at regular intervals during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28634, 30387, 'Topiramate', 'Bone Marrow Failure Disorders', 'The use of carbonic anhydrase inhibitors may rarely cause bone marrow suppression and blood dyscrasias at recommended dosages.  Aplastic anemia, thrombocytopenia or thrombocytopenia purpura, leukopenia, agranulocytosis, and hemolytic anemia have been reported.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered to patients with these preexisting conditions.  A baseline CBC and platelet count is recommended, as well as monitoring at regular intervals during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28635, 3025, 'Topiramate', 'Hyperthermia', 'Oligohidrosis (decreased sweating) and hyperthermia have been reported in association with the use of some carbonic anhydrase inhibitor anticonvulsants such as topiramate and zonisamide.  Most of the reports have been in children.  Caution and close monitoring of body temperature is advised when prescribing these drugs, especially in patients with a fever, in hot weather, or if combined with other drugs that predispose to heat related disorders.  Zonisamide is not approved for use in pediatric patients in the U.S.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28636, 3026, 'Topiramate', 'Hyperthermia', 'Oligohidrosis (decreased sweating) and hyperthermia have been reported in association with the use of some carbonic anhydrase inhibitor anticonvulsants such as topiramate and zonisamide.  Most of the reports have been in children.  Caution and close monitoring of body temperature is advised when prescribing these drugs, especially in patients with a fever, in hot weather, or if combined with other drugs that predispose to heat related disorders.  Zonisamide is not approved for use in pediatric patients in the U.S.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28637, 8555, 'Topiramate', 'Hyperthermia', 'Oligohidrosis (decreased sweating) and hyperthermia have been reported in association with the use of some carbonic anhydrase inhibitor anticonvulsants such as topiramate and zonisamide.  Most of the reports have been in children.  Caution and close monitoring of body temperature is advised when prescribing these drugs, especially in patients with a fever, in hot weather, or if combined with other drugs that predispose to heat related disorders.  Zonisamide is not approved for use in pediatric patients in the U.S.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28638, 11537, 'Topiramate', 'Hyperthermia', 'Oligohidrosis (decreased sweating) and hyperthermia have been reported in association with the use of some carbonic anhydrase inhibitor anticonvulsants such as topiramate and zonisamide.  Most of the reports have been in children.  Caution and close monitoring of body temperature is advised when prescribing these drugs, especially in patients with a fever, in hot weather, or if combined with other drugs that predispose to heat related disorders.  Zonisamide is not approved for use in pediatric patients in the U.S.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28639, 16780, 'Topiramate', 'Hyperthermia', 'Oligohidrosis (decreased sweating) and hyperthermia have been reported in association with the use of some carbonic anhydrase inhibitor anticonvulsants such as topiramate and zonisamide.  Most of the reports have been in children.  Caution and close monitoring of body temperature is advised when prescribing these drugs, especially in patients with a fever, in hot weather, or if combined with other drugs that predispose to heat related disorders.  Zonisamide is not approved for use in pediatric patients in the U.S.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28640, 17218, 'Topiramate', 'Hyperthermia', 'Oligohidrosis (decreased sweating) and hyperthermia have been reported in association with the use of some carbonic anhydrase inhibitor anticonvulsants such as topiramate and zonisamide.  Most of the reports have been in children.  Caution and close monitoring of body temperature is advised when prescribing these drugs, especially in patients with a fever, in hot weather, or if combined with other drugs that predispose to heat related disorders.  Zonisamide is not approved for use in pediatric patients in the U.S.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28641, 18427, 'Topiramate', 'Hyperthermia', 'Oligohidrosis (decreased sweating) and hyperthermia have been reported in association with the use of some carbonic anhydrase inhibitor anticonvulsants such as topiramate and zonisamide.  Most of the reports have been in children.  Caution and close monitoring of body temperature is advised when prescribing these drugs, especially in patients with a fever, in hot weather, or if combined with other drugs that predispose to heat related disorders.  Zonisamide is not approved for use in pediatric patients in the U.S.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28642, 18428, 'Topiramate', 'Hyperthermia', 'Oligohidrosis (decreased sweating) and hyperthermia have been reported in association with the use of some carbonic anhydrase inhibitor anticonvulsants such as topiramate and zonisamide.  Most of the reports have been in children.  Caution and close monitoring of body temperature is advised when prescribing these drugs, especially in patients with a fever, in hot weather, or if combined with other drugs that predispose to heat related disorders.  Zonisamide is not approved for use in pediatric patients in the U.S.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28643, 18429, 'Topiramate', 'Hyperthermia', 'Oligohidrosis (decreased sweating) and hyperthermia have been reported in association with the use of some carbonic anhydrase inhibitor anticonvulsants such as topiramate and zonisamide.  Most of the reports have been in children.  Caution and close monitoring of body temperature is advised when prescribing these drugs, especially in patients with a fever, in hot weather, or if combined with other drugs that predispose to heat related disorders.  Zonisamide is not approved for use in pediatric patients in the U.S.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28644, 27427, 'Topiramate', 'Hyperthermia', 'Oligohidrosis (decreased sweating) and hyperthermia have been reported in association with the use of some carbonic anhydrase inhibitor anticonvulsants such as topiramate and zonisamide.  Most of the reports have been in children.  Caution and close monitoring of body temperature is advised when prescribing these drugs, especially in patients with a fever, in hot weather, or if combined with other drugs that predispose to heat related disorders.  Zonisamide is not approved for use in pediatric patients in the U.S.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28645, 27428, 'Topiramate', 'Hyperthermia', 'Oligohidrosis (decreased sweating) and hyperthermia have been reported in association with the use of some carbonic anhydrase inhibitor anticonvulsants such as topiramate and zonisamide.  Most of the reports have been in children.  Caution and close monitoring of body temperature is advised when prescribing these drugs, especially in patients with a fever, in hot weather, or if combined with other drugs that predispose to heat related disorders.  Zonisamide is not approved for use in pediatric patients in the U.S.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28646, 27429, 'Topiramate', 'Hyperthermia', 'Oligohidrosis (decreased sweating) and hyperthermia have been reported in association with the use of some carbonic anhydrase inhibitor anticonvulsants such as topiramate and zonisamide.  Most of the reports have been in children.  Caution and close monitoring of body temperature is advised when prescribing these drugs, especially in patients with a fever, in hot weather, or if combined with other drugs that predispose to heat related disorders.  Zonisamide is not approved for use in pediatric patients in the U.S.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28647, 28295, 'Topiramate', 'Hyperthermia', 'Oligohidrosis (decreased sweating) and hyperthermia have been reported in association with the use of some carbonic anhydrase inhibitor anticonvulsants such as topiramate and zonisamide.  Most of the reports have been in children.  Caution and close monitoring of body temperature is advised when prescribing these drugs, especially in patients with a fever, in hot weather, or if combined with other drugs that predispose to heat related disorders.  Zonisamide is not approved for use in pediatric patients in the U.S.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28648, 28296, 'Topiramate', 'Hyperthermia', 'Oligohidrosis (decreased sweating) and hyperthermia have been reported in association with the use of some carbonic anhydrase inhibitor anticonvulsants such as topiramate and zonisamide.  Most of the reports have been in children.  Caution and close monitoring of body temperature is advised when prescribing these drugs, especially in patients with a fever, in hot weather, or if combined with other drugs that predispose to heat related disorders.  Zonisamide is not approved for use in pediatric patients in the U.S.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28649, 28297, 'Topiramate', 'Hyperthermia', 'Oligohidrosis (decreased sweating) and hyperthermia have been reported in association with the use of some carbonic anhydrase inhibitor anticonvulsants such as topiramate and zonisamide.  Most of the reports have been in children.  Caution and close monitoring of body temperature is advised when prescribing these drugs, especially in patients with a fever, in hot weather, or if combined with other drugs that predispose to heat related disorders.  Zonisamide is not approved for use in pediatric patients in the U.S.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28650, 28298, 'Topiramate', 'Hyperthermia', 'Oligohidrosis (decreased sweating) and hyperthermia have been reported in association with the use of some carbonic anhydrase inhibitor anticonvulsants such as topiramate and zonisamide.  Most of the reports have been in children.  Caution and close monitoring of body temperature is advised when prescribing these drugs, especially in patients with a fever, in hot weather, or if combined with other drugs that predispose to heat related disorders.  Zonisamide is not approved for use in pediatric patients in the U.S.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28651, 28329, 'Topiramate', 'Hyperthermia', 'Oligohidrosis (decreased sweating) and hyperthermia have been reported in association with the use of some carbonic anhydrase inhibitor anticonvulsants such as topiramate and zonisamide.  Most of the reports have been in children.  Caution and close monitoring of body temperature is advised when prescribing these drugs, especially in patients with a fever, in hot weather, or if combined with other drugs that predispose to heat related disorders.  Zonisamide is not approved for use in pediatric patients in the U.S.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28652, 28330, 'Topiramate', 'Hyperthermia', 'Oligohidrosis (decreased sweating) and hyperthermia have been reported in association with the use of some carbonic anhydrase inhibitor anticonvulsants such as topiramate and zonisamide.  Most of the reports have been in children.  Caution and close monitoring of body temperature is advised when prescribing these drugs, especially in patients with a fever, in hot weather, or if combined with other drugs that predispose to heat related disorders.  Zonisamide is not approved for use in pediatric patients in the U.S.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28653, 28333, 'Topiramate', 'Hyperthermia', 'Oligohidrosis (decreased sweating) and hyperthermia have been reported in association with the use of some carbonic anhydrase inhibitor anticonvulsants such as topiramate and zonisamide.  Most of the reports have been in children.  Caution and close monitoring of body temperature is advised when prescribing these drugs, especially in patients with a fever, in hot weather, or if combined with other drugs that predispose to heat related disorders.  Zonisamide is not approved for use in pediatric patients in the U.S.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28654, 28334, 'Topiramate', 'Hyperthermia', 'Oligohidrosis (decreased sweating) and hyperthermia have been reported in association with the use of some carbonic anhydrase inhibitor anticonvulsants such as topiramate and zonisamide.  Most of the reports have been in children.  Caution and close monitoring of body temperature is advised when prescribing these drugs, especially in patients with a fever, in hot weather, or if combined with other drugs that predispose to heat related disorders.  Zonisamide is not approved for use in pediatric patients in the U.S.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28655, 28339, 'Topiramate', 'Hyperthermia', 'Oligohidrosis (decreased sweating) and hyperthermia have been reported in association with the use of some carbonic anhydrase inhibitor anticonvulsants such as topiramate and zonisamide.  Most of the reports have been in children.  Caution and close monitoring of body temperature is advised when prescribing these drugs, especially in patients with a fever, in hot weather, or if combined with other drugs that predispose to heat related disorders.  Zonisamide is not approved for use in pediatric patients in the U.S.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28656, 30387, 'Topiramate', 'Hyperthermia', 'Oligohidrosis (decreased sweating) and hyperthermia have been reported in association with the use of some carbonic anhydrase inhibitor anticonvulsants such as topiramate and zonisamide.  Most of the reports have been in children.  Caution and close monitoring of body temperature is advised when prescribing these drugs, especially in patients with a fever, in hot weather, or if combined with other drugs that predispose to heat related disorders.  Zonisamide is not approved for use in pediatric patients in the U.S.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28657, 3025, 'Topiramate', 'Liver Failure', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with marked liver disease or cirrhosis.  Carbonic anhydrase inhibitors increase the risk of developing hepatic encephalopathy in these patients.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered in patients with mild to moderate liver disease as the clearance of the drug can be decreased.  A dose reduction might be needed and monitoring of the liver function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28658, 3026, 'Topiramate', 'Liver Failure', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with marked liver disease or cirrhosis.  Carbonic anhydrase inhibitors increase the risk of developing hepatic encephalopathy in these patients.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered in patients with mild to moderate liver disease as the clearance of the drug can be decreased.  A dose reduction might be needed and monitoring of the liver function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28659, 8555, 'Topiramate', 'Liver Failure', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with marked liver disease or cirrhosis.  Carbonic anhydrase inhibitors increase the risk of developing hepatic encephalopathy in these patients.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered in patients with mild to moderate liver disease as the clearance of the drug can be decreased.  A dose reduction might be needed and monitoring of the liver function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28660, 11537, 'Topiramate', 'Liver Failure', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with marked liver disease or cirrhosis.  Carbonic anhydrase inhibitors increase the risk of developing hepatic encephalopathy in these patients.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered in patients with mild to moderate liver disease as the clearance of the drug can be decreased.  A dose reduction might be needed and monitoring of the liver function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28661, 16780, 'Topiramate', 'Liver Failure', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with marked liver disease or cirrhosis.  Carbonic anhydrase inhibitors increase the risk of developing hepatic encephalopathy in these patients.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered in patients with mild to moderate liver disease as the clearance of the drug can be decreased.  A dose reduction might be needed and monitoring of the liver function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28662, 17218, 'Topiramate', 'Liver Failure', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with marked liver disease or cirrhosis.  Carbonic anhydrase inhibitors increase the risk of developing hepatic encephalopathy in these patients.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered in patients with mild to moderate liver disease as the clearance of the drug can be decreased.  A dose reduction might be needed and monitoring of the liver function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28663, 18427, 'Topiramate', 'Liver Failure', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with marked liver disease or cirrhosis.  Carbonic anhydrase inhibitors increase the risk of developing hepatic encephalopathy in these patients.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered in patients with mild to moderate liver disease as the clearance of the drug can be decreased.  A dose reduction might be needed and monitoring of the liver function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28664, 18428, 'Topiramate', 'Liver Failure', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with marked liver disease or cirrhosis.  Carbonic anhydrase inhibitors increase the risk of developing hepatic encephalopathy in these patients.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered in patients with mild to moderate liver disease as the clearance of the drug can be decreased.  A dose reduction might be needed and monitoring of the liver function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28665, 18429, 'Topiramate', 'Liver Failure', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with marked liver disease or cirrhosis.  Carbonic anhydrase inhibitors increase the risk of developing hepatic encephalopathy in these patients.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered in patients with mild to moderate liver disease as the clearance of the drug can be decreased.  A dose reduction might be needed and monitoring of the liver function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28666, 27427, 'Topiramate', 'Liver Failure', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with marked liver disease or cirrhosis.  Carbonic anhydrase inhibitors increase the risk of developing hepatic encephalopathy in these patients.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered in patients with mild to moderate liver disease as the clearance of the drug can be decreased.  A dose reduction might be needed and monitoring of the liver function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28667, 27428, 'Topiramate', 'Liver Failure', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with marked liver disease or cirrhosis.  Carbonic anhydrase inhibitors increase the risk of developing hepatic encephalopathy in these patients.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered in patients with mild to moderate liver disease as the clearance of the drug can be decreased.  A dose reduction might be needed and monitoring of the liver function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28668, 27429, 'Topiramate', 'Liver Failure', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with marked liver disease or cirrhosis.  Carbonic anhydrase inhibitors increase the risk of developing hepatic encephalopathy in these patients.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered in patients with mild to moderate liver disease as the clearance of the drug can be decreased.  A dose reduction might be needed and monitoring of the liver function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28669, 28295, 'Topiramate', 'Liver Failure', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with marked liver disease or cirrhosis.  Carbonic anhydrase inhibitors increase the risk of developing hepatic encephalopathy in these patients.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered in patients with mild to moderate liver disease as the clearance of the drug can be decreased.  A dose reduction might be needed and monitoring of the liver function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28670, 28296, 'Topiramate', 'Liver Failure', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with marked liver disease or cirrhosis.  Carbonic anhydrase inhibitors increase the risk of developing hepatic encephalopathy in these patients.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered in patients with mild to moderate liver disease as the clearance of the drug can be decreased.  A dose reduction might be needed and monitoring of the liver function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28671, 28297, 'Topiramate', 'Liver Failure', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with marked liver disease or cirrhosis.  Carbonic anhydrase inhibitors increase the risk of developing hepatic encephalopathy in these patients.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered in patients with mild to moderate liver disease as the clearance of the drug can be decreased.  A dose reduction might be needed and monitoring of the liver function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28672, 28298, 'Topiramate', 'Liver Failure', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with marked liver disease or cirrhosis.  Carbonic anhydrase inhibitors increase the risk of developing hepatic encephalopathy in these patients.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered in patients with mild to moderate liver disease as the clearance of the drug can be decreased.  A dose reduction might be needed and monitoring of the liver function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28673, 28329, 'Topiramate', 'Liver Failure', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with marked liver disease or cirrhosis.  Carbonic anhydrase inhibitors increase the risk of developing hepatic encephalopathy in these patients.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered in patients with mild to moderate liver disease as the clearance of the drug can be decreased.  A dose reduction might be needed and monitoring of the liver function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28674, 28330, 'Topiramate', 'Liver Failure', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with marked liver disease or cirrhosis.  Carbonic anhydrase inhibitors increase the risk of developing hepatic encephalopathy in these patients.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered in patients with mild to moderate liver disease as the clearance of the drug can be decreased.  A dose reduction might be needed and monitoring of the liver function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28675, 28333, 'Topiramate', 'Liver Failure', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with marked liver disease or cirrhosis.  Carbonic anhydrase inhibitors increase the risk of developing hepatic encephalopathy in these patients.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered in patients with mild to moderate liver disease as the clearance of the drug can be decreased.  A dose reduction might be needed and monitoring of the liver function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28676, 28334, 'Topiramate', 'Liver Failure', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with marked liver disease or cirrhosis.  Carbonic anhydrase inhibitors increase the risk of developing hepatic encephalopathy in these patients.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered in patients with mild to moderate liver disease as the clearance of the drug can be decreased.  A dose reduction might be needed and monitoring of the liver function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28677, 28339, 'Topiramate', 'Liver Failure', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with marked liver disease or cirrhosis.  Carbonic anhydrase inhibitors increase the risk of developing hepatic encephalopathy in these patients.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered in patients with mild to moderate liver disease as the clearance of the drug can be decreased.  A dose reduction might be needed and monitoring of the liver function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28678, 30387, 'Topiramate', 'Liver Failure', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with marked liver disease or cirrhosis.  Carbonic anhydrase inhibitors increase the risk of developing hepatic encephalopathy in these patients.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered in patients with mild to moderate liver disease as the clearance of the drug can be decreased.  A dose reduction might be needed and monitoring of the liver function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28679, 3025, 'Topiramate', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28680, 3026, 'Topiramate', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28681, 8555, 'Topiramate', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28682, 11537, 'Topiramate', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28683, 16780, 'Topiramate', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28684, 17218, 'Topiramate', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28685, 18427, 'Topiramate', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28686, 18428, 'Topiramate', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28687, 18429, 'Topiramate', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28688, 27427, 'Topiramate', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28689, 27428, 'Topiramate', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28690, 27429, 'Topiramate', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28691, 28295, 'Topiramate', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28692, 28296, 'Topiramate', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28693, 28297, 'Topiramate', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28694, 28298, 'Topiramate', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28695, 28329, 'Topiramate', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28696, 28330, 'Topiramate', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28697, 28333, 'Topiramate', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28698, 28334, 'Topiramate', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28699, 28339, 'Topiramate', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28700, 30387, 'Topiramate', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
